Core Viewpoint - Abbott Laboratories reported better-than-expected sales and profits for the second quarter but reduced earnings and growth projections for the remainder of the year [1][2]. Financial Performance - Second-quarter sales reached $11.14 billion, surpassing the consensus estimate of $11.07 billion [1]. - Adjusted earnings for the second quarter were $1.26 per share, exceeding the consensus of $1.25 and falling within the management's guidance of $1.23-$1.27 [1]. Growth Projections - For full-year 2025, Abbott narrowed its adjusted earnings guidance from a range of $5.05-$5.25 per share to $5.10-$5.20 per share, compared to the consensus of $5.16 [2]. - The company expects organic sales growth of 7.5%-8.0%, slightly down from the previous guidance of 7.5%-8.5% [2]. Margin Expectations - Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, unchanged from prior guidance but lower than the previous range of 23.5%-24.0% [3]. - The expected adjusted earnings for the third quarter of 2025 are projected to be between $1.28 and $1.32 per share, below the consensus of $1.34 per share [3]. Market Reaction - Following the earnings announcement, Abbott's shares fell by 8.5%, closing at $120.51 [3]. Analyst Ratings - BTIG analyst maintained a Buy rating but lowered the price target from $148 to $145 [5]. - Jefferies analyst upgraded Abbott from Hold to Buy and raised the price target from $143 to $145 [5]. - Mizuho analyst maintained a Neutral rating and reduced the price target from $140 to $135 [5].